PARP1 and cancer: Furthermore, the PARP inhibitors can also enhance the anticancer activity of PD-1/PD-L1 or the CTLA-4 inhibition, demonstrating that the immunogenic effects of PARP can also be exploited for cancer therapy [60,61].